$-0.74 EPS Expected for ESSA Pharma Inc. (EPIX)

July 14, 2018 - By Jason Dias

ESSA Pharma Inc. (NASDAQ:EPIX) Logo

Analysts expect ESSA Pharma Inc. (NASDAQ:EPIX) to report $-0.74 EPS on August, 13.They anticipate $2.46 EPS change or 76.88 % from last quarter’s $-3.2 EPS. After having $-0.83 EPS previously, ESSA Pharma Inc.’s analysts see -10.84 % EPS growth. The stock decreased 2.75% or $0.11 during the last trading session, reaching $3.89. About 4,840 shares traded. ESSA Pharma Inc. (NASDAQ:EPIX) has declined 92.93% since July 14, 2017 and is downtrending. It has underperformed by 105.50% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $21.92 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.

Another recent and important ESSA Pharma Inc. (NASDAQ:EPIX) news was published by Streetinsider.com which published an article titled: “Form S-1/A AVROBIO, Inc.” on June 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.